StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.48+0.05 (+0.78%)

Close on Nov 17, 2026Market cap $110.85MP/E –Yield –

Atrium Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$13.80M+3.8%
Q2 FY2026Jun 30, 2026$15.34M+121.2%
Q1 FY2026Mar 31, 2026$16.66M–
Q3 FY2025Sep 30, 2025$9.75M–
Q2 FY2025Jun 30, 2025$13.29M–
Q1 FY2025Mar 31, 2025$6.94M–

More Atrium Therapeutics figures

See a number that looks wrong?